Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeyondSpring Inc. (BYSI)
Price$0.6181Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.4M | $1.4M | $180,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $4.4M | $2.6M | $7.3M | $25.6M | $36.9M | $41.8M | $31.3M | $51.6M | $88.9M | $10.4M | $6.3M | $1.9M |
| Operating expenses | $8.9M | $8.8M | $15.1M | $38.6M | — | — | — | — | — | — | — | — |
| Operating income | −$8.9M | −$8.8M | −$15.1M | −$37.2M | −$66.2M | −$64.2M | −$40.3M | −$57.5M | −$98.0M | −$12.4M | −$7.5M | −$2.1M |
| Operating margin | — | — | — | −2,756.40% | −4,903.03% | −35,672.78% | — | — | — | — | — | — |
| EBITDA | −$8.9M | −$8.5M | −$14.8M | −$37.0M | −$66.2M | −$64.1M | −$40.2M | −$57.5M | −$97.9M | −$12.3M | −$7.5M | −$2.1M |
| EBITDA margin | — | — | — | −2,739.23% | −4,898.52% | −35,630.00% | — | — | — | — | — | — |
| Net income | −$1.0M | −$11.1M | −$21.0M | −$33.3M | −$64.2M | −$61.0M | −$38.1M | −$54.9M | −$91.8M | −$12.0M | −$8.0M | −$3.0M |
| Net profit margin | — | — | — | −2,463.29% | −4,750.48% | −33,873.89% | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.02 | -$0.28 | -$0.54 | -$0.85 | -$1.64 | -$2.03 | -$1.55 | -$2.42 | -$4.40 | -$0.75 | -$0.53 | -$0.22 |
| Diluted EPSper diluted share | -$0.02 | -$0.28 | -$0.54 | -$0.85 | -$1.64 | -$2.03 | -$1.55 | -$2.42 | -$4.40 | -$0.75 | -$0.53 | -$0.22 |
Owners
Reported shareholders
≈9.80%of listed shares
Decheng Capital China Life Sciences USD Fund II, L.P. / Decheng Capital China Life Sciences USD Fund III, L.P. / Decheng Capital Management III (Cayman), LLC / Decheng Capital Management II (Cayman), LLC / Decheng Capital Global Healthcare GP, LLC / Cui Xiangmin / Decheng Capital Global Healthcare Fund (Master), LP4.03M shares · Oct 17, 2025
View holders
| Holder | % owned |
|---|---|
Decheng Capital China Life Sciences USD Fund II, L.P. / Decheng Capital China Life Sciences USD Fund III, L.P. / Decheng Capital Management III (Cayman), LLC / Decheng Capital Management II (Cayman), LLC / Decheng Capital Global Healthcare GP, LLC / Cui Xiangmin / Decheng Capital Global Healthcare Fund (Master), LP | ≈9.80%4.03M shares |
Decheng Capital LLC | 9.24%3.8M shares |
BlackRock, Inc. | 1.64%672.92K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.52%626.46K shares |
Huang Lan | ≈1.16%476.76K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.89%367.74K shares |
STATE STREET CORP | 0.56%231.12K shares |
VANGUARD FIDUCIARY TRUST CO | 0.44%181.2K shares |
UBS Group AG | 0.15%63.03K shares |
NORTHERN TRUST CORP | 0.15%62.02K shares |
Majeti Jiangwen | ≈0.12%50.91K shares |
Fabbio Patrick | ≈0.06%24.59K shares |
Meridian Wealth Management, LLC | 0.04%15K shares |
Farther Finance Advisors, LLC | 0.03%12.77K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.03%10.9K shares |
Vanguard Global Advisers, LLC | 0.01%4.8K shares |
MORGAN STANLEY | 0.01%4.57K shares |
NATIONAL BANK OF CANADA /FI/ | <0.01%2.88K shares |
Trifecta Capital Advisors, LLC | <0.01%1.5K shares |
Tower Research Capital LLC (TRC) | <0.01%1.47K shares |
Percentages use 41.12M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 17, 2025Form 4 | Decheng Capital China Life Sciences USD Fund II, L.P. +6TenPercentOwner | SellOrdinary Shares · indirect | 45.5K | $1.76 | $80.1K | 1.52M |
| Oct 16, 2025Form 4 | Decheng Capital China Life Sciences USD Fund II, L.P. +6TenPercentOwner | SellOrdinary Shares · indirect | 85.8K | $1.72 | $147.6K | 1.56M |
| Oct 15, 2025Form 4 | Decheng Capital Global Healthcare GP, LLC +6TenPercentOwner | SellOrdinary Shares · indirect | 18.0K | $1.65 | $29.6K | 1.65M |
| Oct 14, 2025Form 4 | Decheng Capital Global Healthcare GP, LLC +6TenPercentOwner | SellOrdinary Shares · indirect | 28.5K | $1.65 | $47.0K | 1.67M |
| Oct 13, 2025Form 4 | Decheng Capital Global Healthcare GP, LLC +6TenPercentOwner | SellOrdinary Shares · indirect | 107.4K | $1.70 | $182.5K | 1.70M |
Community posts
BeyondSpring secures Fast Track status and trades China subsidiary for trial funding
BeyondSpring ($BYSI) said the FDA granted Fast Track designation to plinabulin plus docetaxel for a defined previously treated non-squamous lung-cancer population. Separately, it signed an agreement to sell the holding company controlling i ...
